← FormularyTracking · Category 2

Peptide · Body Protection Compound

BPC-157

Soft-tissue & gut recovery

Status
On watchlist — not yet prescribable

Mechanism

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in gastric juice. It promotes angiogenesis via VEGF upregulation, accelerates tendon-to-bone healing, and has demonstrated gastroprotective effects in animal models. It appears to modulate nitric oxide signaling and growth hormone receptor expression.

Indications

Tendon and ligament repair
Gut mucosal healing (IBD, leaky gut models)
Muscle injury recovery
Anti-inflammatory effects

Regulatory status

BPC-157 was moved to the FDA 503A Category 2 bulk substances list in 2023, making it ineligible for routine compounding. HHS has signaled intent to review reclassification. Northline does not prescribe Category 2 substances. Members are first notified on any FDA ruling.

References

01Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2018.
02FDA 503A Category 2 — currently ineligible for compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.